Preparation for treatment of spinal cord injury

A technology of preparation and sustained-release preparation, applied in the field of medicine for local treatment of spinal cord injury

Inactive Publication Date: 2013-06-05
SUMITOMO DAINIPPON PHARMA CO LTD +1
View PDF12 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no practical sustained-release formulations suitable for topical administration of compounds of formula (1) have yet been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation for treatment of spinal cord injury
  • Preparation for treatment of spinal cord injury
  • Preparation for treatment of spinal cord injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0145] L-HPC (low substituted hydroxypropyl cellulose) (90 mg) and vinaxanthone powder (6 mg) were mixed in a mortar to produce a mixed powder. SILASTIC Q7-4750 Silicone A Component (102 mg) and Silicone B Component (102 mg) manufactured by Dow Corning were kneaded together using a double roller. After kneading the above-mentioned silicone, all of the above-obtained mixed powders were quickly added thereto, and the mixture was kneaded. Then, the kneaded product was rolled into a sheet shape using a double roller and cured at 40° C. for 1 day to yield a sheet preparation with a thickness of 0.3 mm. The sheet formulation was cut to produce Formulation 1.

Embodiment 2

[0152] To lactose (45 mg) was added L-HPC (45 mg) followed by vinaxanthone powder (6 mg) in a mortar and all three powders were mixed together to produce a mixed powder. SILASTIC Q7-4750 silicone A component (102 mg) and silicone B component (102 mg) manufactured by Dow Corning were kneaded together using a double roller. After kneading the above-mentioned silicone, all of the above-obtained mixed powders were quickly added thereto, and the mixture was kneaded. Then, the kneaded product was rolled into a sheet shape using a double roller and cured at 40° C. for 1 day to yield a sheet preparation with a thickness of 0.3 mm. The sheet formulation was cut to produce Formulation 2.

Embodiment 3

[0154] Crystalline sodium chloride was ground in a mortar to adjust its particle diameter to 100 μm or less, wherein the particle size was checked using an optical microscope (phase contrast microscope BX-51-33-PHU-D, OLYMPAS). To the sodium chloride (15 mg) obtained above was added L-HPC (75 mg) and then vinaxanthone powder (6 mg), and all three powders were mixed together in a mortar to produce a mixed powder. SILASTIC Q7-4750 silicone A component (102 mg) and silicone B component (102 mg) manufactured by Dow Corning were kneaded together using a double roller. After kneading the above-mentioned silicone, all of the above-obtained mixed powders were quickly added thereto, and the mixture was kneaded. Then, the kneaded product was rolled into a sheet shape using a double roller and cured at 40° C. for 1 day to yield a sheet preparation with a thickness of 0.3 mm. The sheet formulation was cut to produce Formulation 3.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to view more

Abstract

The present invention is a solid sustained-release formulation comprising an agent for inhibiting semaphorin 3A as an active ingredient, which comprises an agent for inhibiting semaphorin 3A and pharmaceutically acceptable hardly water-soluble solid substance, in which the carrier is silicone.

Description

technical field [0001] The present invention provides a medicament for local treatment of spinal cord injury, which comprises, as an active ingredient, a compound of formula (1) described later or a pharmaceutically acceptable salt thereof, which has an activity of inhibiting semaphorin 3A. That is, the present invention relates to a solid controlled-release preparation using a biocompatible polymer as a carrier, which is suitable for implantation near the site of spinal cord injury, and which can effectively inhibit the Reagent delivery of semaphorin 3A to the site of injury. In detail, the preparation of the present invention can be implanted in the subdural space adjacent to the injured spinal cord and effectively deliver the active ingredient to the injured site to exert the effect of the active ingredient within about one month required for nerve regeneration. Background technique [0002] Neurons are atypical cells in organisms that do not have the ability to divide. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K9/00A61K9/70A61K47/02A61K47/28A61K47/34A61K47/38A61P25/00A61P43/00
CPCA61K47/02A61K9/0024A61K47/28A61K9/0085A61K47/34A61K47/38A61K31/352A61K9/7007A61P25/00A61P43/00A61P7/00
Inventor 前田美穗岸野晶祥佐野明彦冈野荣之中村雅也张亮
Owner SUMITOMO DAINIPPON PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products